Natural killer cells inhibit hepatitis C virus expression

Journal of Leukocyte Biology

Volumn 76, Issue 6, 2004, Pages 1171-1179

  Li, Yuan ^a   Zhang, Ting ^a   Ho, Chun ^a   Orange, Jordan S ^a   Douglas, Steven D ^a   Ho, Wen Zhe ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

CD81; Interferon; STAT

Indexed keywords

CD81 ANTIGEN; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; SOLUBLE FACTOR; STAT1 PROTEIN; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CELL LINE; CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS LINKING; CULTURE MEDIUM; CYTOLYSIS; CYTOTOXICITY; GENE EXPRESSION REGULATION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNITY; IMMUNOASSAY; INTERFERON PRODUCTION; LIVER CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPLICON; VIRUS EXPRESSION; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIGENS, CD; ANTIVIRAL AGENTS; BIOLOGICAL ASSAY; CELL LINE; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; DNA-BINDING PROTEINS; DOWN-REGULATION; HEPACIVIRUS; HEPATOCYTES; HUMANS; IMMUNITY, NATURAL; INTERFERON TYPE II; INTERFERON-ALPHA; KILLER CELLS, NATURAL; RECEPTORS, INTERFERON; REPRESSOR PROTEINS; RNA, VIRAL; STAT1 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 10044294010     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0604372     Document Type: Article

References (47)

1. Choo, Q. L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W., Houghton, M. (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359-362.
2. Alter, M. J., Margolis, H. S., Krawczynski, K., Judson, F. N., Mares, A., Alexander, W. J., Hu, P. Y., Miller, J. K., Gerber, M. A., Sampliner, R. E. (1992) The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic Non-A, Non-B Hepatitis Study Team. N. Engl. J. Med. 327, 1899-1905.
3. Alter, M. J., Kruszon-Moran, D., Nainan, O. V., McQuillan, G. M., Gao, F., Moyer, L. A., Kaslow, R. A., Margolis, H. S. (1999) The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 341, 556-562.
4. Tong, M. J., el-Farra, N. S., Reikes, A. R., Co, R. L. (1995) Clinical outcomes after transfusion-associated hepatitis C. N. Engl. J. Med. 332, 1463-1466.
5. Kiyosawa, K., Sodeyama, T., Tanaka, E., Gibo, Y., Yoshizawa, K., Nakano, Y., Furuta, S., Akahane, Y., Nishioka, K., Purcell, R. H. (1990) Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 12, 671-675.
6. Racanelli, V., Rehermann, B. (2003) Hepatitis C virus infection: when silence is deception. Trends Immunol. 24, 456-464.
7. Alter, H. J., Seeff, L. B. (2000) Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin. Liver Dis. 20, 17-35.
8. Davis, G. L., Esteban-Mur, R., Rustgi, V., Hoefs, J., Gordon, S. C., Trepo, C., Shiffman, M. L., Zeuzem, S., Craxi, A., Ling, M. H., Albrecht, J. (1998) Interferon α-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339, 1493-1499.
9. McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffmann, M. L., Lee, W. M., Rustgi, V. K., Goodmann, Z. D., Ling, M. H., Cort, S., Albrecht, J. K. (1998) Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339, 1485-1492.
10. Nuti, S., Rosa, D., Valiante, N. M., Saletti, G., Caratozzolo, M., Dellabona, P., Barnaha, V., Abrignani, S. (1998) Dynamics of intra-hepatic lymphocytes in chronic hepatitis C: enrichment for Vα24+ T cells and rapid elimination of effector cells by apoptosis. Eur. J. Immunol. 28, 3448-3455.
11. Bianchi, L. (1983) Liver biopsy interpretation in hepatitis. Part II: histopathology and classification of acute and chronic viral hepatitis/differential diagnosis. Pathol. Res. Pract. 178, 180-213.
12. Biron, C. A., Nguyen, K. B., Pien, G. C., Cousens, L. P., Salazar-Mather, T. P. (1999) Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 17, 189-220.
13. Crotta, S., Stilla, A., Wack, A., D'Audrea, A., Nuti, S., D'Oro, U., Mosca, M., Filliponi, F., Brunetto, R. M., Bonino, F., Abrignani, S., Valiante, N. M. (2002) Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J. Exp. Med. 195, 35-41.
14. Tseng, C. T., Klimpel, G. R. (2002) Binding of the hepatitis C virus envelope protein E2 to CD81 inbibits natural killer cell functions. J. Exp. Med. 195, 43-49.
15. Lohmann, V., Korner, F., Koch, J., Herian, U., Theilmann, L., Bartenschlager, R. (1999) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 110-113.
16. Blight, K. J., Kolykhalov, A. A., Rice, C. M. (2000) Efficient initiation of HCV RNA replication in cell culture. Science 290, 1972-1974.
17. Rosenberg, S. (2001) Recent advances in the molecular biology of hepatitis C virus. J. Mol. Biol. 313, 451-464.
18. Gong, J. H., Maki, G., Klingemann, H. G. (1994) Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8, 652-658.
19. Cohen, G. B., Gandhi, R. T., Davis, D. M., Mandelboim, O., Chen, B. K., Strominger, J. L., Baltimore, D. (1999) The selective downregulation of class 1 major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 10, 661-671.
20. Nakabayashi, H., Taketa, K., Miyano, K., Yamane, T., Sato, J. (1982) Growth of human hepatoma cell lines with differentiated functions in chemically defined medium. Cancer Res. 42, 3858-3863.
21. Yang, J. H., Lai, J. P., Douglas, S. D., Metzger, D., Zhu, X. H., Ho, W. Z. (2002) Real-time RT-PCR for quantitation of hepatitis C virus RNA. J. Virol. Methods 102, 119-128.
22. Guo, J. T., Bichko, V. V., Seeger, C. (2001) Effect of α interferon on the hepatitis C virus replicon. J. Virol. 75, 8516-8523.
23. Li, Y., Zhang, T., Douglas, S. D., Lai, J-P., Xiao, W-D., Pleasure, D. E., Ho, W-Z. (2003) Morphine enhances hepatitis C virus (HCV) replicon expression. Am. J. Pathol. 163, 1167-1175.
24. Douglas, S. D., Durako, S. J., Tustin, N. B., Houser, J., Muenz, L., Starr, S. E., Wilson, C., Adolescent Medicine, H. I. V. A. R. N. (2001) Natural killer cell enumeration and function in HIV-infected and high-risk uninfected adolescents. AIDS Res. Hum. Retroviruses 17, 543-552.
25. Zhang, T., Li, Y., Lai, J. P., Douglas, S. D., Metzger, D. S., O'Brien, C. P., Ho, W. Z. (2003) Alcohol potentiates hepatitis C virus replicon expression. Hepatology. 38, 57-65.
26. Sharma, S., tenOever, B. R., Grandvaux, N., Zhou, G. P., Lin, R., Hiscott, J. (2003) Triggering the interferon antiviral response through an IKK-related pathway. Science 300, 1148-1151.
27. Biron, C. A. (1997) Activation and function of natural killer cell responses during viral infections. Curr. Opin. Immunol. 9, 24-34.
28. Levy, S., Todd, S. C., Maecker, H. T. (1998) CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu. Rev. Immunol. 16, 89-109.
29. Bach, E. A., Aguet, M., Schreiber, R. D. (1997) The IFN γ receptor: a paradigm for cytokine receptor signaling. Annu. Rev. Immunol. 15, 563-591.
30. Orange, J. S., Wang, B., Terhorst, C., Biron, C. A. (1995) Requirement for natural killer cell-produced interferon γ in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration. J. Exp. Med. 182, 1045-1056.
31. Frese, M., Schwarzle, V., Barth, K., Krieger, N., Lohmann, V., Mihm, S., Haller, O., Bartenschlager, R. (2002) Interferon-γ inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 35, 694-703.
32. Liu, C., Zhu, H., Tu, Z., Xu, Y. L., Nelson, D. R. (2003) CD8+ T-cell interaction with HCV replicon cells: evidence for both cytokine- and cell-mediated antiviral activity. Hepatology 37, 1335-1342.
33. Meraz, M. A., White, J. M., Sheehan, K. C., Bach, E. A., Rodig, S. J., Dighe, A. S., Kaplan, D. H., Riley, J. K., Greenlund, A. C., Campbell, D., Carver-Moore, K., DuBois, R. N., Clark, R., Aguet, M., Schreiber, R. D. (1996) Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84, 431-442.
34. Durbin, J. E., Hackenmiller, R., Simon, M. C., Levy, D. E. (1996) Targeted disruption of the mouse Statl gene results in compromised innate immunity to viral disease. Cell 84, 443-450.
35. Doherty, D. G., O'Farrelly, C. (2000) Innate and adaptive lymphoid cells in the human liver. Immunol. Rev. 174, 5-20.
36. Seki, S., Habu, Y., Kawamura, T., Takeda, K., Dobashi, H., Ohkawa, T., Hiraide, H. (2000) The liver as a crucial organ in the first line of host defense: the roles of Kupffer cells, natural killer (NK) cells and NK1.1 Ag+ T cells in T helper 1 immune responses. Immunol. Rev. 174, 35-46.
37. Gale Jr., M. J., Korth, M. J., Tang, N. M., Tan, S. L., Hopkins, D. A., Dever, T. E., Polyak, S. J., Gretch, D. R., Katze, M. G. (1997) Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230, 217-227.
38. Taylor. D. R., Shi, S. T., Romano, P. R., Barber, G. N., Lai, M. M. (1999) Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285, 107-110.
39. Large, M. K., Kittlesen, D. J., Hahn, Y. S. (1999) Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J. Immunol. 162, 931-938.
40. Lanier, L. L., Phillips, J. H. (1996) Inhibitory MHC class I receptors on NK cells and T cells. Immunol. Today 17, 86-91.
41. Corado, J., Toro, F., Rivera, H., Bianco, N. E., Deibis, L., De Sanctis, J. B. (1997) Impairment of natural killer (NK) cytotoxic activity in hepatitis C virus (HCV) infection. Clin. Exp. Immunol. 109, 451-457.
42. Moradpour, D., Blum, H. E. (1999) Current and evolving therapies for hepatitis C. Eur. J. Gastroenterol. Hepatol. 11, 1199-1202.
43. Zeuzem, S., Feinman, S. V., Rasenack, J., Heathcote, E. J., Lai, M. Y., Gane, E., O'Grady, J., Reichen, J., Diago, M., Lin, A., Hoffman, J., Brunda, M. J. (2000) Peginterferon α-2a in patients with chronic hepatitis C. N. Engl. J. Med. 343, 1666-1672.
44. Heathcote, E. J., Shiffman, M. L., Cooksley, W. G., Dusheiko, G. M., Lee, S. S., Balart, L., Reindollar, R., Reddy, R. K., Wright, T. L., Lin, A., Hoffman, J., De Pamphilis, J. (2000) Peginterferon α-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 343, 1673-1680.
45. Katayama, K., Kasahara, A., Sasaki, Y., Kashiwagi, T., Naito, M., Masuzawa, M., Katoh, M., Yoshihara, H., Kamada, T., Mukuda, T., Hijioka, T., Hori, M., Hayashi, N. (2001) Immunological response to interferon-γ priming prior to interferon-α treatment in refractory chronic hepatitis C in relation to viral clearance. J. Viral Hepat. 8, 180-185.
46. Kumashiro, R., Ide, T., Sasaki, M., Murashima, S., Suzuki, H., Hino, T., Morita, Y., Miyajima, I., Ogata, K., Tanaka, E., Yoshida, H., Tanikawa, K., Sata, M. (2002) Interferon-γ brings additive anti-viral environment when combined with interferon-α in patients with chronic hepatitis C. Hepatol. Res. 22, 20-26.
47. Saez-Royuela, F., Porres, J. C., Moreno, A., Castillo, I., Martinez, G., Galiana, F., Carreno, V. (1991) High doses of recombinant α-interferon or γ-interferon for chronic hepatitis C: a randomized, controlled trial. Hepatology 13, 327-331.